After Crizotinib FDA approval, Capmatinib and Tepotinib were approved for metastatic NSCLC in patients with MET exon 14 (METex14) skipping mutation [136], as one of the main mutations, which contributes to NSCLC independently [137]. The gene discussed is MET; the disease is non-small cell lung carcinoma.